β-cell stimulation by saxagliptin in patients with type 2 diabetes by Henry, Robert et al.
■ Sequential IV-oral hyperglycaemic clamp and arginine stimulation 
tests performed on Day -1 and Day 84 (Figure 2):
– IV Hyperglycaemic Clamp [0–180 min]:
• SAXA or PBO administered 30 min before beginning of 
glucose infusion to achieve hyperglycaemia
with plasma glucose = 280 mg/dL.
• Plasma glucose then maintained at 280 mg/dL by 
adjusted glucose infusion rate.
– IV-Oral Hyperglycaemic Clamp [180–480 min]:
• 75 g glucose administered orally at 180 min.
• Plasma glucose maintained at 280 mg/dL by adjusted 
glucose infusion rate.
– Arginine Stimulation Test  [480–515 min]:
• Prior to start of arginine infusion, glucose infusion 
increased to achieve and maintain plasma glucose 
= 450 mg/dL.
• Arginine 5 g (10% solution, 50 mL IV over 30 sec) 
administered at 505 min.
■ Glucose, insulin, and glucagon measurements were drawn at 
designated intervals prior to starting and during the infusion process. 
■ Analytical technique for insulin secretion rate measured by 
C-peptide deconvolution.8-10
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■ Three-centre, phase 3, randomised, parallel-group, double-blind, 
placebo-controlled trial with IV-oral hyperglycaemic clamp to assess 
the effect of SAXA on β-cell function in T2DM patients (Figure 1):
– 2-week single-blind diet and exercise PBO lead-in phase.
– 12-week double-blind treatment phase.
■ Patients were randomised to receive once daily SAXA 
5 mg or PBO.
■ Diabetes is Australia’s fastest growing chronic disease with 
approximately 890,000 patients currently diagnosed with diabetes.1
By 2031 it is predicted that 3.3 million Australians will have type 2 
diabetes2 thus increasing the demand for prevention strategies and 
an emphasis on early diagnosis and treatment. Saxagliptin (SAXA) 
is a potent, selective DPP-4 inhibitor, specifically designed for 
extended inhibition of the DPP-4 enzyme. DPP-4 inactivates 
incretins that stimulate glucose-dependent insulin secretion and 
inhibit glucagon secretion. A proposed MOA of SAXA involves 
protecting incretins from DPP-4 degradation, thus improving β-cell 
response. This randomised, parallel-group, double-blind, PBO-
controlled study (CV181-041) assessed SAXA’s effect on β-cell 
function by intravenous hyperglycaemic clamp (IV HC) in T2DM 
patients.
■ Patients were assessed at baseline (BL) and wk 12 in the fasting
state (0-180min, IV HC) and after stimulating incretin secretion by 
orally ingesting 75g glucose (180-480min, IV-oral HC). HC infusions 
were adjusted to maintain plasma glucose at 280mg/dL. Insulin 
secretion was calculated by C-peptide deconvolution. Primary 
endpoint was %Δ from BL in total insulin secretion (%Δ insulin) 
during IV-oral HC (180-480min). Secondary endpoint was %Δ insulin 
during IV HC (120-180min). Patients were drug-naïve with T2DM 
aged 43-69yrs with BL A1C range 5.9%-8.1%. Twenty patients 
received SAXA 5mg od; 16 received PBO. 
■ After 12 wks, SAXA significantly increased %Δ insulin from BL 
during IV-oral HC (adj% difference of 18.5% vs PBO, p=.035). In the 
fasting state during IV HC SAXA significantly increased %Δ insulin 
from BL (adj% difference of 27.9% vs PBO, p=.020). At wk 12 insulin 
secretion increased from BL with SAXA but not with PBO (Fig). 
Glucagon AUC during IV-oral HC also improved from BL with SAXA, 
(adj% difference of –21.8% vs PBO, p=.031). SAXA was generally 
safe and well-tolerated. 
■ In conclusion, SAXA improved pancreatic β-cell function in the 
postprandial and fasting states and decreased postprandial 
glucagon concentration.
■ The endogenous incretins glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic peptide (GIP) regulate blood 
glucose via mechanisms that include stimulation of glucose-
dependent insulin secretion and inhibition of glucagon secretion.
■ GLP-1 and GIP are secreted in response to enteral nutrient loads, 
but are rapidly cleaved and inactivated by dipeptidyl peptidase-4 
(DPP-4).  
■ Saxagliptin (SAXA) is a potent, selective DPP-4 inhibitor, specifically 
designed for extended inhibition of the DPP-4 enzyme.3
■ Previously reported trials of SAXA in patients with type 2 diabetes 
mellitus (T2DM) have demonstrated efficacy and safety of SAXA 
as monotherapy and in combination with other oral antidiabetic
agents.4-7
■ The proposed mechanism of action of SAXA involves protecting 
incretins from DPP-4 degradation, thereby improving β-cell response 
and decreasing glucagon secretion.
■ This trial utilized a sequential intravenous and intravenous-oral 
hyperglycaemic clamp to study the mechanism of action of SAXA. 
Trial endpoints compared changes in β-cell responsiveness and 
insulin secretion rates in drug-naïve T2DM patients who received 
either SAXA 5 mg or placebo for 12 weeks (Trial # CV181-041). 
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*Glucose infusion to achieve and maintain hyperglycaemia = 280 mg/dL from 
0 – 480 min.  At 480 min, infusion adjusted to maintain hyperglycaemia = 
450 mg/dL.
†Arginine 5 g (10% solution, 50 mL IV over 30 sec) administered at 505 min.
‡Samples drawn at protocol-specified intervals.
Figure 2. Sequential IV-Oral Hyperglycaemic Clamp and Arginine
Stimulation Test 
■ Study objectives (SAXA 5 mg vs PBO at 12 weeks):
– Primary: Percent change from baseline in total insulin 
secretion during IV-oral hyperglycaemic clamp (180–480 min).
– Secondary: Percent change from baseline in total insulin 
secretion during IV hyperglycaemic clamp (120–180 min). 
– Tertiary:
• Percent changes from baseline in insulin secretion 
following IV arginine stimulation.
• Changes from baseline in GLP-1 and GIP 
concentrations during IV-oral hyperglycaemic clamp.
• Changes from baseline in glucagon assessments 
during IV-oral and IV hyperglycaemic clamp. 
– Safety and tolerability of SAXA 5 mg.
■ Efficacy analyses were performed using an ANCOVA model utilising
last observation carried forward (LOCF).
Table 1. Patient Demographics and Baseline Characteristics
(21.5)124.7(22.0)131.5FPG, mg/dL, mean (SD)
(0.6)6.6(0.5)6.9HbA1c, %, mean (SD)
(4.0)3.7(4.4)2.7T2DM duration, y, mean (SD)
(3.9)32.2(3.7)33.5BMI, kg/m2, mean (SD) 
(13.5)92.5(15.0)95.0Weight, kg, mean (SD)
(62.5)10(60.0)12Gender, female, n (%)
(6.9)56.2(8.6)55.2Age, y, mean (SD)
PBO (n=16)SAXA 5 mg (n=20)
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Insulin Secretion Rates During Postprandial and Fasting States
■ At week 12, insulin secretion increased from baseline with 
SAXA but not with PBO:
– In the postprandial state (Primary endpoint –
Figures 3 and 5).
– In the fasting state (Secondary endpoint –
Figures 4 and 5).
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Figure 3. Insulin Secretion Rate During IV-Oral Hyperglycaemic Clamp: 
Adjusted % Change from Baseline at Week 12 (LOCF)  
Figure 4. Insulin Secretion Rate During IV Hyperglycaemic Clamp: 
Adjusted % Change From Baseline at Week 12 (LOCF)
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*Values are geometric means.
†Adjusted % change from baseline, geometric mean and 95% CI 
(represented by bar).
*Values are geometric means.
†Adjusted % change from baseline, geometric mean and 95% CI 
(represented by bar).
Insulin Secretion Rate (pmol/kg)*
SAXA PBO 
Baseline: 2818      3687 
Week 12  (LOCF): 3303      3564  
Adjusted % difference vs PBO (95% CI): 18.5 (1,3,38.7)
P = 0.035
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Insulin Secretion Rate (pmol/kg)*
SAXA PBO 
Baseline: 446      594 
Week 12  (LOCF): 552      563  
Adjusted % difference vs PBO (95% CI): 27.9 (4.2,57.1)
P = 0.020
RESULTS (continued)
Figure 5. Insulin Secretion Rates During Hyperglycaemic Clamp in 
Fasting (0–180 min) and Postprandial Conditions 
(180–480 min) at Baseline and Week 12 (LOCF)
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Insulin Secretion Following Stimulation with IV Arginine
■ At week 12, percent changes in insulin secretion and acute 
insulin response to IV arginine were numerically greater for 
SAXA than PBO (Table 2), although not statistically 
significant.
Table 2. Insulin Secretion Following IV Arginine: Changes from 
Baseline at Week 12
(n = 14)(n = 16)Acute insulin response, μU/mL
204  (175, 268)164  (107, 203)Baseline, median (Q1, Q3)
185  (147, 208)172  (136, 228)Week 12, median (Q1, Q3)
-21.7 (-52.3, 5.3)24.0
† (-5.8, 
71.5)
Change from baseline*, median 
(Q1, Q3)
PBOSAXA 5 mgInsulin secretion in first 5 minutes following IV arginine
*LOCF, last observation carried forward.
†P value vs PBO = 0.074 (Kruskal-Wallis test).
GLP-1 and GIP Concentrations During IV-Oral Hyperglycaemic Clamp
■ At week 12, SAXA increased peak concentrations of intact, 
active GLP-1 and GIP following oral glucose stimulation 
during IV-oral hyperglycaemic clamp (Figures 6 and 7).
Figure 6. Active GLP-1 Concentrations During IV-Oral 
Hyperglycaemic Clamp at Baseline and Week 12 (LOCF)
Figure 7. Active GIP Concentrations During IV-Oral Hyperglycaemic
Clamp at Baseline and Week 12 (LOCF)
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■ Compared to placebo, 12 weeks of treatment with SAXA 5 mg in 
drug-naïve T2DM patients:
– Increased pancreatic β-cell responsiveness to glucose in the 
postprandial state during IV-oral hypoglycaemic clamp.
– Increased pancreatic β-cell responsiveness to glucose in the 
fasting state during IV hypoglycaemic clamp.
– Increased peak levels of intact, active GLP-1 and GIP 
following oral glucose stimulation.
– Lowered postprandial glucagon secretion.
■ Thus, saxagliptin improves glycaemic parameters in patients with 
T2DM by inhibiting the degradation of incretins and reducing 
postprandial glucagon secretion.
■ Saxagliptin was generally well tolerated, with a safety profile 
consistent with that observed in prior large
Phase 3 studies.
Table 3. Glucagon Secretion: Changes from Baseline at Week 12
-3352*
(-6371, -333)Difference vs PBO, mean  (95% CI)   
1161 
(-1014, 3336)
-2191 
(-4153, -229)
Adjusted change from baseline, 
mean (95% CI)
12965 (1273)11571 (1113)Week 12 LOCF, mean (SE)
11177 (880)14279 (1228)Baseline mean (SE)
(n = 15)(n = 18)Mean glucagon concentration during IV clamp, pg/mL
(n = 14)(n = 17)Glucagon AUC during IV-oral clamp, pg*min/mL
36.8 (3.43)50.2 (3.54)Baseline, mean (SE)
45.5 (3.95)41.7 (3.75)Week 12 LOCF, mean (SE)
5.5 
(-2.2, 13.2)
-5.7
(-12.6, 1.3)
Adjusted change from baseline, 
mean (95% CI)
PBOSAXA 5 mgParameter
AUC, area under the curve; LOCF, last observation carried forward, ANCOVA model.
*P value vs PBO = 0.031.
Glycaemic Control
■ Glycaemic parameters are summarized in Table 4.
Table 4. Glycaemic Control at Week 12
6.6 (0.17)6.8 (0.16)Week 12 LOCF,  mean (SE)
0.02
(-0.23, 0.28)
-0.14
(-0.38, 0.10)
Adjusted change from baseline, 
mean (95% CI)
6.6 (0.14)6.9 (0.12)Baseline, mean (SE)
FPG, mg/dL
HbA1c %
124.7 (5.37)133.2 (5.29)Baseline, mean (SE)
138.2 (6.19)134.6 (7.01)Week 12 LOCF, mean (SE)
12.4
(0.8, 23.9)
2.4
(-8.5, 13.3)
Adjusted change from baseline, 
mean (95% CI)
PBO 
(n = 16)
SAXA 5 mg 
(n = 18)Glycaemic Parameters
LOCF, last observation carried forward.
■ SAXA 5 mg was well tolerated.
■ There were no deaths, serious AEs, or discontinuations due to AEs.
■ AEs reported for >1 subject per treatment group included headache 
(SAXA, n=3; PBO, n=1), muscle spasms (SAXA, n=3), sinusitis 
(SAXA, n=2), parasthesia (SAXA, n=2), infusion site pain (SAXA, 
n=2), fatigue (PBO, n=2), cough (PBO, n=2), and sinus congestion
(PBO, n=2). 
■ Compared with PBO, SAXA was not associated with a meaningful 
increase in hypoglycaemia, infections, localised oedema, or 
cardiovascular events.
Glucagon Secretion
■ The change from baseline at week 12 in glucagon AUC during 
IV-oral hyperglycaemic clamp in the SAXA group was 
significantly different from the PBO group (Table 3).
■ During IV hyperglycaemic clamp, mean glucagon concentration 
decreased in the SAXA group, and increased in the PBO group 
(Table 3).
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